Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
GFPT2 (HGNC:4242) has been implicated in the pathogenesis of type 2 diabetes mellitus (MONDO:0005148) through multiple large-scale association studies. In a cohort of Caucasian and African‑American individuals, several common single nucleotide polymorphisms (SNPs) in GFPT2 were found to be associated with type 2 diabetes and diabetic nephropathy, suggesting a role for this gene in modulating disease risk (PMID:14764791). The study reported that the variant found in exon 14, which corresponds to c.1411A>G (p.Ile471Val), appears to alter the amino acid sequence and is evolutionarily conserved. This genetic association is further supported by additional findings in an independent study that identified trends of association with diabetic chronic renal insufficiency in subjects with type 2 diabetes (PMID:20353610). Overall, the population data underscore a consistent relationship between GFPT2 variation and susceptibility to type 2 diabetes mellitus.
The genetic evidence encompasses data from case series and multi‑patient cohort studies where multiple SNPs in GFPT2, including the coding change c.1411A>G (p.Ile471Val), have been statistically associated with type 2 diabetes. These variants were evaluated in diverse ethnic groups and several genotype‑phenotype correlations were noted, giving credence to the potential impact of GFPT2 on glucose metabolism. Although family‐based segregation data were not formally provided, the replication of associations in independent cohorts highlights the robustness of the findings. The evidence suggests that while no extensive segregation of variants among affected relatives was documented, the strength of population associations is compelling. This cumulative evidence positions GFPT2 as a gene with a significant influence on metabolic control and diabetes risk.
From the genetic standpoint, the recurrent identification of common GFPT2 SNPs, particularly the missense variant c.1411A>G (p.Ile471Val), provides a molecular basis for disease involvement. The presence of this variant in multiple association studies indicates a reproducible effect across different populations. Moreover, the observed association signals in both Caucasian and African‑American individuals reinforce the gene’s contribution to type 2 diabetes susceptibility. The variant spectrum in GFPT2 appears to be largely composed of common missense changes with modest effect sizes that collectively influence disease risk. These observations support the designation of the gene‑disease association as being of high clinical relevance.
In addition to the genetic association, functional assessments have provided moderate supportive evidence linking GFPT2 to diabetes. Studies evaluating the promoter activity of GFPT2 have demonstrated that its transcriptional regulation is critical for proper enzyme levels within the hexosamine biosynthetic pathway (PMID:11167021). Increased GFPT2 mRNA levels were observed in transformed lymphocytes from African‑American subjects, independent of diagnosis, suggesting that overexpression of GFPT2 may contribute to dysregulated glucose metabolism. This upregulation is posited to lead to augmented hexosamine flux, a pathway previously implicated in insulin resistance and beta‑cell dysfunction. Thus, the experimental evidence aligns with the genetic data, indicating that altered GFPT2 expression has a plausible mechanistic role in type 2 diabetes pathogenesis.
The integration of both genetic and functional evidence provides a coherent narrative that positions GFPT2 as a strong candidate gene in the pathophysiology of type 2 diabetes mellitus. Although the studies predominantly assess common variant associations rather than rare high‐penetrance mutations, the convergence of statistical associations and experimental data collectively strengthen the clinical validity of the association. No significant conflicting evidence has emerged to detract from this association, although some studies have focused on related phenotypes such as diabetic nephropathy and chronic kidney disease, which further underscores the multifactorial impact of GFPT2. The consistency of these findings across different study designs bolsters confidence in the role of GFPT2 in diabetes.
By linking common genetic variations in GFPT2 with altered gene expression and an increased flux through the hexosamine biosynthetic pathway, the evidence supports a model in which GFPT2 contributes to metabolic dysregulation observed in type 2 diabetes. While the effect sizes of individual SNPs may be modest, their additive impact and replication across studies highlight their clinical importance. It is notable that additional functional experiments have validated the transcriptional consequences of these variants, thereby bridging population genetics with molecular mechanisms. Furthermore, the functional studies provide data that may inform future therapeutic strategies aimed at modulating GFPT2 activity.
Key to the clinical utility of these findings is the reproducibility of the association across diverse populations and the demonstrable functional impact of GFPT2 variants. Together, the evidence indicates that GFPT2 is a genetically and functionally validated contributor to type 2 diabetes mellitus, offering potential for its use in diagnostic decision‑making and as a target for pharmacological interventions. The combined genetic and functional data not only support the assignment of a strong clinical validity classification but also emphasize the gene’s utility in guiding future research and commercial applications in diabetes care.
Gene–Disease AssociationStrongMultiple independent association studies in diverse populations, including statistically significant SNP associations and consistent trends across studies (PMID:14764791, PMID:20353610). Genetic EvidenceStrongThe presence of common missense variants, notably c.1411A>G (p.Ile471Val), in multi‑patient cohorts provides robust genetic evidence for involvement in type 2 diabetes with reproducible associations across ethnic groups. Functional EvidenceModerateFunctional assays demonstrate that GFPT2 promoter activity regulates gene expression levels, with increased GFPT2 mRNA implicated in augmented hexosamine flux, a known factor in diabetes pathogenesis (PMID:11167021). |